Nuvation Bio Inc. Reports Officer and Director Changes
Ticker: NUVB · Form: 8-K · Filed: Feb 12, 2025 · CIK: 1811063
Sentiment: neutral
Topics: management-change, corporate-governance
Related Tickers: NUVA
TL;DR
NUVA board/exec shakeup effective Feb 11.
AI Summary
Nuvation Bio Inc. filed an 8-K on February 12, 2025, reporting changes effective February 11, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. Specific details regarding the individuals involved, their roles, and the nature of the compensatory arrangements are not provided in this excerpt.
Why It Matters
Changes in a company's board of directors or executive officers can signal shifts in strategy, governance, or operational focus.
Risk Assessment
Risk Level: medium — Changes in key personnel can indicate underlying issues or strategic shifts that may impact the company's future performance.
Key Players & Entities
- Nuvation Bio Inc. (company) — Registrant
- February 11, 2025 (date) — Effective date of reported changes
- February 12, 2025 (date) — Filing date of the 8-K
- Panacea Acquisition Corp (company) — Former company name
FAQ
What specific changes were made regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers, but the specific individuals and their roles are not detailed in this excerpt.
What is the effective date of the reported changes?
The earliest event reported is dated February 11, 2025.
When was this 8-K filing submitted to the SEC?
The filing was submitted on February 12, 2025.
What is Nuvation Bio Inc.'s state of incorporation?
Nuvation Bio Inc. is incorporated in Delaware.
What was Nuvation Bio Inc.'s former company name?
Nuvation Bio Inc. was formerly known as Panacea Acquisition Corp.
Filing Stats: 566 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-02-12 16:05:16
Key Financial Figures
- $0.0001 — which registered Class A Common Stock, $0.0001 par value per share NUVB The New Yo
- $11.50 — of Common Stock at an exercise price of $11.50 per share NUVB.WS The New York Stoc
Filing Documents
- d839065d8k.htm (8-K) — 24KB
- 0001193125-25-025099.txt ( ) — 182KB
- nuvb-20250211.xsd (EX-101.SCH) — 4KB
- nuvb-20250211_def.xml (EX-101.DEF) — 14KB
- nuvb-20250211_lab.xml (EX-101.LAB) — 23KB
- nuvb-20250211_pre.xml (EX-101.PRE) — 15KB
- d839065d8k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NUVATION BIO INC. Date: February 12, 2025 By: /s/ David Hung, M.D. Name: David Hung, M.D. Title: Chief Executive Officer